04-09-2001

FORM PTO-1618A Expires 06/20/99

101658263

U.S. Department of Commerce Patent and Trademark Office

,a 280	•
MRD 1819386	
	ION FORM COVER SHEET
	EMARKS ONLY
	s: Please record the attached original document(s) or copy(ies).
Submission Type X New	Conveyance Type X Assignment License
Resubmission (Non-Recordation) Document ID #	Security Agreement Nunc Pro Tunc Assignme
Correction of PTO Error Reel # Frame #	Merger Month Day Year 03312001 Change of Name
Corrective Document Reel # Frame #	Other
Conveying Party	Mark if additional names of conveying parties attached Execution Date Month Day Yea
Name Elan Pharmaceuticals, I	
Formerly	
Individual General Partnership	Limited Partnership Corporation Association
	> ~ ~
Other	
	zation Delaware Delaware
X Citizenship/State of Incorporation/Organi Receiving Party	zation Delaware Delaware Mark if additional names of receiving parties attached
X Citizenship/State of Incorporation/Organi Receiving Party Name Xcel Pharmaceuticals	zation Delaware Delaware Mark if additional names of receiving parties attached
X Citizenship/State of Incorporation/Organi Receiving Party Name Xcel Pharmaceuticals DBA/AKA/TA	zation Delaware Mark if additional names of receiving parties attached Inc.
X Citizenship/State of Incorporation/Organi Receiving Party Name Xcel Pharmaceuticals	zation Delaware Signature
X Citizenship/State of Incorporation/Organic Receiving Party Name Xcel Pharmaceuticals DBA/AKA/TA Composed of	zation Delaware Signature
X Citizenship/State of Incorporation/Organic Receiving Party Name Xcel Pharmaceuticals DBA/AKA/TA Composed of Address (line 1) 7475 Lusk Boulev Address (line 2) Address (line 3) San Diego	zation Delaware Solve attached Solve
X Citizenship/State of Incorporation/Organia Receiving Party Name Xcel Pharmaceuticals DBA/AKA/TA Composed of Address (line 1) 7475 Lusk Boulev Address (line 2)	Zation Delaware Mark if additional names of receiving parties attached Tip. CA State/Country If document to be recorded is an
X Citizenship/State of Incorporation/Organi: Receiving Party Name Xcel Pharmaceuticals DBA/AKA/TA Composed of Address (line 1) 7475 Lusk Boulev Address (line 2) Address (line 3) San Diego City	Delaware Mark if additional names of receiving parties attached Inc. CA State/Country Limited Partnership If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic
X Citizenship/State of Incorporation/Organic Receiving Party Name Xcel Pharmaceuticals DBA/AKA/TA Composed of 7475 Lusk Boulev Address (line 1) 7475 Lusk Boulev Address (line 2) City Individual General Partnership	Zation Delaware Mark if additional names of receiving parties attached The state/Country State/Country If document to be recorded is an assignment and the receiving party is not domiciled in the United States, and

Public burden reporting for this collection of information is estimated to average approximately 10 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and present of the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and present of the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and present of the U.S. Patent and Patent and

	•			
FORM PTO-1618B Expires 08/30/99 OM8 0651-0027	Pa	ge 2	U.S. Department of Commerce Patent and Trademark Office TRADEMARK	
Domestic Repres	entative Name and Address	Enter for the first Rec	eiving Party only.	
Name				
Address (line 1)				
Address (line 2)				
Address (line 3)				
Address (line 4)				
Correspondent Name and Address Area Code and Telephone Number (415) 442-1325				
Name	Gerald Rita			
Address (line 1) c/o Brobeck, Phleger & Harrison LLP				
Address (line 2) Spear Street Tower - One Market				
Address (line 3)	San Francisco, CA 94105			
Address (line 4)				
. 4400	the total number of pages of the ding any attachments.	attached conveyance doc	ument # 5	
Trademark Application Number(s) or Registration Number(s) Mark if additional numbers attached				
• •	nark Application Number or the Registration	· · · · · · · · · · · · · · · · · · ·	 	
	Application Number(s)		ation Number(s)	
		1819386		
·				
Number of Properties Enter the total number of properties involved. # 1				
Fee Amount	Fee Amount for Propertie	s Listed (37 CFR 3.41):	\$ 40.00	
Method of Payment: Enclosed X Deposit Account Deposit Account				
(Enter for payment by deposit account or if additional fees can be charged to the account.) Deposit Account Number: #				
	Authorization	to charge additional fees:	Yes No	
Statement and Signature				
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.				
Gerald	Rita	Deeld Kita	4/5/2001	
Name of Per	rson Signing	Signature	Date Signed	

TRADEMARK ASSIGNMENT

(DIASTAT)

THIS TRADEMARK ASSIGNMENT dated as of March 31, 2001, among Elan Pharmaceuticals, Inc., a Delaware corporation, having its principal offices at 800 Gateway Blvd., South San Francisco, California 94080 ("Assignor") and Xcel Pharmaceuticals, Inc., a Delaware corporation, having its principal offices at 7475 Lusk Blvd., San Diego, CA 92121 ("Assignee").

BACKGROUND

- A. Assignor's predecessor in interest adopted, used, and Assignor is presently using and is the owner of the entire right, title and interest in and to the DIASTAT trademarks in connection with its pharmaceutical business, including registrations and applications therefor, identified in Schedule A attached hereto (hereinafter the "Trademarks");
- B. Assignee desires to acquire Assignor's entire right, title and interest in and to the Trademarks;
- C. Assignor makes this assignment pursuant to that certain Diastat Asset Purchase Agreement, dated March 31, 2001, by and among Assignor and Assignee ("Asset Purchase Agreement"), under which Assignee purchased certain Purchased Assets (as defined therein) from Assignor, including but not limited to the Trademarks and the products therefor; and
- D. NOW, THEREFORE, for good and valuable consideration stated in the Asset Purchase Agreement, the receipt and adequacy of which is hereby acknowledged, the parties agree as follows:
- 1. Assignor does hereby sell, assign, and transfer unto Assignee the entire right, title and interest of Assignor in and to the Trademarks, together with the goodwill of the business symbolized by said Trademarks and associated therewith.
- 2. Assignor covenants and agrees that it will, upon the reasonable request of the Assignee, execute and deliver, any and all documents provided by Assignee that may be necessary or desirable to transfer to Assignee, its successors or other legal representative, the Assignor's right, title and interest in and to such Trademarks.
- 3. Except as set forth in the Asset Purchase Agreement, Assignor makes no warranty, express or implied, with respect to the Trademarks involved in this assignment and Assignee shall have no recourse against Assignor therefor.

4. If Assignee elects to record this assignment or any other document or transfer with the appropriate U.S. or foreign governmental authorities or registries, Assignee shall bear the costs and fees associated with recording, but Assignor shall provide timely cooperation to Assignee as reasonably necessary.

SDIL(B1\SKI\366083.02(7%GZ02!.DOC)

2014

03/29/01 THU 12:23 FAX 650 794 5712 ELAN CONFIDENTIAL

MAR 29 2001 02:05 FR BROBECK

TO 6956#014395#0044 P.07

IN WITNESS WHEREOF, each party has caused its proper officer to execute this Trademark Assignment effective as of March 31, 2001.

ELAN PHARMACEUTICALS, INC.

Title: Viu President ; Suratary

XCEL PHARMACEUTICALS, INC.

By:__ Name:

Title:

SDILIB1\SKI\366083.02(7%GZ021.DOC)

IN WITNESS WHEREOF, each party has caused its proper officer to execute this Trademark Assignment effective as of March 31, 2001.

ELAN PHARMACEUTICALS, INC.

By:_____Name:

Title:

XCEL PHARMACEUTICALS, INC.

Name:

Title:

SCHEDULE A TRADEMARK ASSIGNMENT

治而治力自治治下及中央 地域的影響	HARBONOLARP NOT H	
DIASTAT	TMA465,699	Canada
DIASTAT	1,084,444	Canada
DIASTAT	1,819,386	United States

SDILIB1\SKJ\366083.02(7%GZ02!.DOC)